Trial Profile
A randomized, double-blind, adaptive single-ascending-dose SAD/MAD/FE phase I study of RG-7816 in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2018
Price :
$35
*
At a glance
- Drugs Alogabat (Primary)
- Indications Autistic disorder
- Focus Adverse reactions
- 26 Feb 2018 New trial record